Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy
David Gyori, … , Len R. Stephens, Phillip T. Hawkins
David Gyori, … , Len R. Stephens, Phillip T. Hawkins
Published June 7, 2018
Citation Information: JCI Insight. 2018;3(11):e120631. https://doi.org/10.1172/jci.insight.120631.
View: Text | PDF
Research Article Immunology Oncology

Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy

  • Text
  • PDF
Abstract

Redundancy and compensation provide robustness to biological systems but may contribute to therapy resistance. Both tumor-associated macrophages (TAMs) and Foxp3+ regulatory T (Treg) cells promote tumor progression by limiting antitumor immunity. Here we show that genetic ablation of CSF1 in colorectal cancer cells reduces the influx of immunosuppressive CSF1R+ TAMs within tumors. This reduction in CSF1-dependent TAMs resulted in increased CD8+ T cell attack on tumors, but its effect on tumor growth was limited by a compensatory increase in Foxp3+ Treg cells. Similarly, disruption of Treg cell activity through their experimental ablation produced moderate effects on tumor growth and was associated with elevated numbers of CSF1R+ TAMs. Importantly, codepletion of CSF1R+ TAMs and Foxp3+ Treg cells resulted in an increased influx of CD8+ T cells, augmentation of their function, and a synergistic reduction in tumor growth. Further, inhibition of Treg cell activity either through systemic pharmacological blockade of PI3Kδ, or its genetic inactivation within Foxp3+ Treg cells, sensitized previously unresponsive solid tumors to CSF1R+ TAM depletion and enhanced the effect of CSF1R blockade. These findings identify CSF1R+ TAMs and PI3Kδ-driven Foxp3+ Treg cells as the dominant compensatory cellular components of the immunosuppressive tumor microenvironment, with implications for the design of combinatorial immunotherapies.

Authors

David Gyori, Ee Lyn Lim, Francis M. Grant, Dominik Spensberger, Rahul Roychoudhuri, Stephen J. Shuttleworth, Klaus Okkenhaug, Len R. Stephens, Phillip T. Hawkins

×

Figure 3

Depletion of CSF1R+ macrophages synergizes with genetic ablation of Foxp3+ Treg cells.

Options: View larger image (or click on image) Download as PowerPoint
Depletion of CSF1R+ macrophages synergizes with genetic ablation of Foxp...
(A and B) In vivo growth curves (A) and primary tumor masses at day 21 (B) of WT and Csf1–/– MC38 tumor cells implanted s.c. at day 0 into WT and Foxp3DTR mice treated with 25 μg/kg diphtheria toxin (DTx) i.p. (C–G) Representative flow panels (C) and quantification of the F4/80+ (D) CSF1R+ (E), Foxp3+ (F), and CD8+ (G) immune cell infiltrates of WT and Csf1–/– MC38 tumors isolated from WT and Foxp3DTR mice treated with DTx. Graphs show mean ± SEM of data from 10 individual mice per group. **P < 0.01; ***P < 0.001; ****P < 0.0001 by 2-way ANOVA.

Copyright © 2022 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts